APA (7th ed.) Citation

JS, M., KA, H., JM, Y., JC, W., JG, K., S, P., & CY, P. (2026). Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: A 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. Diabetes research and clinical practice, 236, 113272. https://doi.org/10.1016/j.diabres.2026.113272

Chicago Style (17th ed.) Citation

JS, Moon, Han KA, Yu JM, Won JC, Kang JG, Park S, and Park CY. "Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-week Randomized, Double-blind, Placebo-controlled Phase 3 Trial with 28-week Open-label Extension." Diabetes Research and Clinical Practice 236 (2026): 113272. https://doi.org/10.1016/j.diabres.2026.113272.

MLA (9th ed.) Citation

JS, Moon, et al. "Efficacy and Safety of Anagliptin Added to Metformin and Empagliflozin 25 mg in Patients with Type 2 Diabetes: A 24-week Randomized, Double-blind, Placebo-controlled Phase 3 Trial with 28-week Open-label Extension." Diabetes Research and Clinical Practice, vol. 236, 2026, p. 113272, https://doi.org/10.1016/j.diabres.2026.113272.